Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care.

Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality.

To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape.

Defining the Endovascular Procedure Landscape

Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, peripheral, neurovascular, and venous procedures. Collectively, these categories represent a substantial volume of global clinical activity.

Based on data shared in Microbot’s past presentations, there are approximately 6 million applicable procedures annually in the U.S. and close to 15 million worldwide that could theoretically benefit from robotic assistance.

Why Peripheral and Neurovascular Matter in Endovascular Robotics

Two factors shape where robotic systems are most likely to gain traction early: disease prevalence and procedural complexity.

From a prevalence standpoint, peripheral and venous disease affect a massive patient population. Estimates suggest 8 to 10 million adults in the U.S. live with peripheral artery disease, while chronic venous disease impacts more than 25 million adults. When ranked by prevalence in the U.S., the burden of disease falls in this order: peripheral, coronary, neurovascular.

Complexity tells a different but complementary story. Neurovascular interventions are generally the most technically demanding, followed by peripheral procedures, with coronary work often considered the most standardized. In endovascular care, complexity matters because surgical robotics tend to offer the most value when precision, navigation, and operator fatigue become limiting factors.

By reducing technical burden and improving control, robotic assistance has the potential to expand access to treatment while improving consistency across operators.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/microbot-medical-and-the-endovascular-robotics-opportunity-taking-shape

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more